Why did GAAP EPS fall so sharply in Q4 2023 while non-GAAP EPS rose?

The gap is driven by acquisition accounting from the Horizon Therapeutics deal. GAAP cost of sales rose to 39.7% of product sales, largely from amortization of acquired intangible assets, and SG&A rose 45% on acquisition-related costs. Non-GAAP results exclude these noncash and one-time items, so the non-GAAP EPS increase of 15% reflects underlying operations, including Horizon's contribution.

How much debt did Amgen take on, and is leverage a concern?

Total debt rose to $64.6 billion at year-end 2023 from $38.9 billion a year earlier, mainly to fund Horizon. Debt leverage was about 4.4 times EBITDA. Management highlights that free cash flow and EBITDA are the basis for this ratio, but leverage is elevated relative to historical levels, and higher interest expense weighed on Q4 non-GAAP EPS.

Why did free cash flow decline in 2023?

Full-year free cash flow fell to $7.4 billion from $8.8 billion, primarily due to Horizon transaction expenses and higher repatriation tax payments. Q4 free cash flow was only $0.3 billion, reflecting the timing of federal and repatriation tax payments.

What is the outlook for 2024?

Amgen guided to total revenues of $32.4 to $33.8 billion, non-GAAP EPS of $18.90 to $20.30, and GAAP EPS of $8.42 to $9.87, with capital expenditures of about $1.1 billion and share repurchases of up to $500 million. The wide GAAP range reflects expected acquisition-related amortization of roughly $10.43 to $10.48 per share.

What key regulatory and pipeline events should investors watch in 2024?

The FDA set a June 12, 2024 PDUFA date for tarlatamab in second-line small cell lung cancer and a June 21, 2024 PDUFA date for BLINCYTO in early-stage B-ALL. Other notable readouts include the olpasiran Phase 3 cardiovascular outcomes study (enrollment completion expected H1 2024), the rocatinlimab HORIZON study and the Nplate chemotherapy-induced thrombocytopenia study (both H2 2024), and maridebart cafraglutide Phase 2 topline data in late 2024.

AMGN 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed February 6, 2024. Cited figures are marked; the original filing is the authoritative source.

Amgen reported fourth-quarter and full-year 2023 results on February 6, 2024, with the headline story being a sharp GAAP earnings decline in Q4 driven by acquisition accounting from the Horizon Therapeutics deal, offset by strong underlying product growth.

Q4 total revenues rose 20% to $8.2 billion^a, with product sales up 20% on 23% volume growth. Horizon contributed $954 million of sales from October 6 to December 31, and excluding Horizon, product sales grew 5%. Q4 GAAP diluted EPS fell 53% to $1.42 from $3.00, while non-GAAP EPS rose 15% to $4.71.

For the full year, GAAP EPS rose 3% to $12.49^b (helped by a $1.5 billion equity gain on BeiGene), while non-GAAP EPS rose 5% to $18.65. The balance sheet and cash flow picture warrants attention. Total debt climbed to $64.6 billion from $38.9 billion, and leverage stood at about 4.4 times EBITDA.

Full-year free cash flow fell to $7.4 billion^c from $8.8 billion, driven by Horizon transaction costs and higher repatriation tax payments. Q4 free cash flow was only $0.3 billion. Management guided 2024 total revenues to $32.4 to $33.8 billion, non-GAAP EPS to $18.90 to $20.30, and GAAP EPS to $8.42 to $9.87, and repurchases are capped at $500 million.

Investors should weigh the Horizon-driven growth and pipeline catalysts, including tarlatamab and BLINCYTO PDUFA dates in June 2024, against the elevated leverage and the substantial GAAP-to-non-GAAP gap. The filing itself is a routine Item 2.02 disclosure furnishing the earnings release as Exhibit 99.1, with non-GAAP reconciliations provided. It does not contain new strategic announcements beyond what is in the release.

02—Key points

Key Highlights

Q4 2023 total revenues rose 20% to $8.2 billion; product sales grew 20% on 23% volume growth, and excluding Horizon, product sales grew 5%.
Horizon Therapeutics contributed $954 million of product sales from October 6 to December 31, 2023, including TEPEZZA ($448M), KRYSTEXXA ($272M), and UPLIZNA ($65M) for the period.
Q4 GAAP diluted EPS fell 53% to $1.42 from $3.00 due to acquisition-related expenses, while non-GAAP EPS rose 15% to $4.71.
Full-year 2023 GAAP EPS rose 3% to $12.49, aided by $1.5 billion in net gains on the BeiGene equity investment; non-GAAP EPS rose 5% to $18.65.
Full-year free cash flow fell to $7.4 billion from $8.8 billion; total debt rose to $64.6 billion, with debt leverage at about 4.4x EBITDA.
2024 guidance: total revenues of $32.4 to $33.8 billion, non-GAAP EPS of $18.90 to $20.30, GAAP EPS of $8.42 to $9.87, and share repurchases capped at $500 million.
Key 2024 catalysts include PDUFA dates of June 12, 2024 (tarlatamab) and June 21, 2024 (BLINCYTO in early-stage B-ALL), plus Phase 3 readouts for olpasiran, rocatinlimab, and other programs in H2 2024.

03—Questions

Frequently Asked Questions

Why did GAAP EPS fall so sharply in Q4 2023 while non-GAAP EPS rose?
The gap is driven by acquisition accounting from the Horizon Therapeutics deal. GAAP cost of sales rose to 39.7% of product sales, largely from amortization of acquired intangible assets, and SG&A rose 45% on acquisition-related costs. Non-GAAP results exclude these noncash and one-time items, so the non-GAAP EPS increase of 15% reflects underlying operations, including Horizon's contribution.
How much debt did Amgen take on, and is leverage a concern?
Total debt rose to $64.6 billion at year-end 2023 from $38.9 billion a year earlier, mainly to fund Horizon. Debt leverage was about 4.4 times EBITDA. Management highlights that free cash flow and EBITDA are the basis for this ratio, but leverage is elevated relative to historical levels, and higher interest expense weighed on Q4 non-GAAP EPS.
Why did free cash flow decline in 2023?
Full-year free cash flow fell to $7.4 billion from $8.8 billion, primarily due to Horizon transaction expenses and higher repatriation tax payments. Q4 free cash flow was only $0.3 billion, reflecting the timing of federal and repatriation tax payments.
What is the outlook for 2024?
Amgen guided to total revenues of $32.4 to $33.8 billion, non-GAAP EPS of $18.90 to $20.30, and GAAP EPS of $8.42 to $9.87, with capital expenditures of about $1.1 billion and share repurchases of up to $500 million. The wide GAAP range reflects expected acquisition-related amortization of roughly $10.43 to $10.48 per share.
What key regulatory and pipeline events should investors watch in 2024?
The FDA set a June 12, 2024 PDUFA date for tarlatamab in second-line small cell lung cancer and a June 21, 2024 PDUFA date for BLINCYTO in early-stage B-ALL. Other notable readouts include the olpasiran Phase 3 cardiovascular outcomes study (enrollment completion expected H1 2024), the rocatinlimab HORIZON study and the Nplate chemotherapy-induced thrombocytopenia study (both H2 2024), and maridebart cafraglutide Phase 2 topline data in late 2024.

04—Continue

← View all 8-K filings